OneMedNet Announces Exciting New Collaboration with Bayer's AI Innovation Platform to Help Accelerate Healthcare AI Development
OneMedNet (Nasdaq: ONMD) has announced a collaboration with Bayer's AI Innovation Platform (AIIP). The partnership combines OneMedNet's regulatory-grade real-world data platform, which aggregates data from over 1,400 healthcare provider facilities, with Bayer's AIIP. This integration aims to provide developers with comprehensive tools and precise datasets for creating effective and compliant AI-powered medical imaging software products, ultimately working to improve patient outcomes.
OneMedNet (Nasdaq: ONMD) ha annunciato una collaborazione con la Piattaforma di Innovazione AI di Bayer (AIIP). Questa partnership combina la piattaforma di dati del mondo reale, conforme alle normative, di OneMedNet, che aggrega dati provenienti da oltre 1.400 strutture sanitarie, con l'AIIP di Bayer. Questa integrazione ha l'obiettivo di fornire agli sviluppatori strumenti completi e dataset precisi per la creazione di software per immagini mediche alimentato dall'IA, efficaci e conformi, lavorando infine per migliorare i risultati per i pazienti.
OneMedNet (Nasdaq: ONMD) ha anunciado una colaboración con la Plataforma de Innovación en IA de Bayer (AIIP). La asociación combina la plataforma de datos del mundo real, de calidad regulatoria, de OneMedNet, que agrega datos de más de 1,400 instalaciones de proveedores de atención médica, con la AIIP de Bayer. Esta integración tiene como objetivo proporcionar a los desarrolladores herramientas completas y conjuntos de datos precisos para crear productos de software de imágenes médicas impulsados por IA, en última instancia trabajando para mejorar los resultados de los pacientes.
원메드넷 (Nasdaq: ONMD)는 바이엘의 AI 혁신 플랫폼 (AIIP)과 협력 관계를 발표했습니다. 이 파트너십은 1,400개 이상의 의료 서비스 제공 시설에서 데이터를 집계하는 원메드넷의 규제 기준 현실 세계 데이터 플랫폼과 바이엘의 AIIP를 결합합니다. 이 통합은 개발자에게 효과적이고 규정을 준수하는 AI 기반 의료 영상 소프트웨어 제품을 만드는 데 필요한 포괄적인 도구와 정확한 데이터 세트를 제공하는 것을 목표로 하며, 궁극적으로 환자 결과 개선을 위해 노력합니다.
OneMedNet (Nasdaq: ONMD) a annoncé une collaboration avec la Plateforme d'Innovation en IA de Bayer (AIIP). Ce partenariat combine la plateforme de données du monde réel, conforme aux réglementations, de OneMedNet, qui agrège des données provenant de plus de 1 400 établissements de santé, avec l'AIIP de Bayer. Cette intégration vise à fournir aux développeurs des outils complets et des ensembles de données précis pour créer des produits logiciels d’imagerie médicale alimentés par IA, travaillant finalement à améliorer les résultats pour les patients.
OneMedNet (Nasdaq: ONMD) hat eine Zusammenarbeit mit der AI-Innovationsplattform von Bayer (AIIP) bekannt gegeben. Die Partnerschaft kombiniert die regulierungsfähige Plattform für Daten aus der realen Welt von OneMedNet, die Daten aus über 1.400 Gesundheitseinrichtungen aggregiert, mit der AIIP von Bayer. Diese Integration soll Entwicklern umfassende Werkzeuge und präzise Datensätze zur Verfügung stellen, um wirksame und konforme KI-gestützte Softwareprodukte für die medizinische Bildgebung zu erstellen, und letztendlich die Patientenergebnisse zu verbessern.
- Access to data from 1,400+ healthcare provider facilities
- Strategic partnership with major healthcare company Bayer
- Expansion into AI development tools market
- None.
Insights
This collaboration marks a strategic move in the healthcare AI development space, combining OneMedNet's extensive real-world data network with Bayer's AI innovation capabilities. The partnership's value lies in the access to data from over 1,400 healthcare facilities, providing a robust foundation for AI model development and validation.
The integration could potentially accelerate OneMedNet's market position in the growing healthcare AI sector, though immediate revenue impact remains unclear. The deal enhances the company's competitive position by partnering with a major pharmaceutical player, potentially attracting more healthcare organizations and startups to their platform.
However, with a small market cap of
MINNEAPOLIS, Dec. 02, 2024 (GLOBE NEWSWIRE) -- OneMedNet Corporation (Nasdaq: ONMD) ("OneMedNet" or the "Company"), a Real-World Data (RWD) platform — has announced its collaboration with Bayer's AI Innovation Platform (AIIP). By joining AIIP, the partnership aims to empower the developer teams of healthcare organizations and startups in building scalable and compliant AI-powered medical imaging software products.
"We are thrilled to join forces with Bayer's AI Innovation Platform," said Aaron Green, CEO & President of OneMedNet. "This collaboration allows us to combine our regulatory-grade real-world data platform, which aggregates data from our provider network of over 1,400 healthcare provider facilities, with Bayer's innovative AIIP. Together, we aim to empower developers to create advanced AI solutions that can significantly improve patient outcomes."
The partnership underscores the importance of collaboration in addressing the diverse requirements of healthcare AI development. By integrating OneMedNet's robust iRWDä platform with Bayer's AIIP, developers will have access to comprehensive tools and the precise datasets necessary for creating effective and compliant AI healthcare applications.
About OneMedNet Corporation
OneMedNet provides innovative solutions that are designed to unlock the significant value contained within the Real-World Data (“RWD”) repositories of over 1,400 healthcare system and provider sites that currently comprise its iRWD™ network. OneMedNet’s proprietary iRWD™ platform provides secure, comprehensive management of diverse clinical data types, including electronic health records, ECGs, EEGs, prescriptions, physician notes, laboratory results, and uniquely, medical imaging. Employing its robust iRWD™ platform, the Company securely de-identifies, searches, and curates the clinical data, bringing a wealth of internal and third-party research opportunities to its drug, medical device and imaging/diagnostic AI development customers.
OneMedNet’s platform is designed to address diverse clinical requirements across various domains, such as rare diseases, central nervous system disorders, oncology, cardiology and women’s health. The Company is committed to delivering precise and robust research support services that span the entire continuum of care. This commitment is a cornerstone of OneMedNet’s strategy to enhance patient outcomes and help pave the next wave of healthcare innovation. For more information, please visit www.onemednet.com.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements. In addition, from time to time, we or our representatives may make forward-looking statements orally or in writing. We base these forward-looking statements on our expectations and projections about future events, which we derive from the information currently available to us. Such forward-looking statements relate to future events or our future performance, including: our financial performance and projections; our growth in revenue and earnings; and our business prospects and opportunities. You can identify forward-looking statements by those that are not historical in nature, particularly those that use terminology such as "may," "should," "expects," "anticipates," "contemplates," "estimates," "believes," "plans," "projected," "predicts," "potential," or "hopes" or the negative of these or similar terms. In evaluating these forward-looking statements, you should consider various factors, including: our ability to change the direction of OneMedNet; our ability to keep pace with new technology and changing market needs; the competitive environment of our business; the timeline for the Company to regain compliance with the listing rules of The Nasdaq Stock Market LLC relating to the timely filing of periodic reports with the SEC; risks inherent with investing in Bitcoin, including Bitcoin's volatility; and our ability to implement our Bitcoin treasury strategy and its effects on our business. These and other factors may cause our actual results to differ materially from any forward-looking statement. Forward-looking statements are only predictions. The forward-looking events discussed in this press release and other statements made from time to time by us or our representatives, may not occur, and actual events and results may differ materially and are subject to risks, uncertainties, and assumptions about us. We are not obligated to publicly update or revise any forward-looking statement, whether as a result of uncertainties and assumptions, the forward-looking events discussed in this press release and other statements made from time to time by us or our representatives might not occur.
OneMedNet Contacts:
Michael Wong, VP of Marketing
Email: michael.wong@onemednet.com
SOURCE: ONEMEDNET CORPORATION
FAQ
What is OneMedNet's new partnership with Bayer announced in December 2024?
How many healthcare facilities are in OneMedNet's (ONMD) provider network?
What is the purpose of OneMedNet's (ONMD) collaboration with Bayer's AIIP?
